Back

Comparative study of the effects of preferential left ventricular and biventricular pacing on echocardiographic and cardiorespiratory indices and clinical status of heart failure patients: preliminary

2 September 2024 (10:55 - 11:05)
Organised by: Logo
Congress Presentation Part of: Fighting ventricular dyssynchrony: cardiac resynchronisation therapy vs. conduction-system pacing Device Treatment ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Panagiotis Xydis

Hippokrateion Hospital Athens, Athens (Greece)

4 More presentations in this session

Presentation thumbnail
Impact of QRS complex fragmentation on all-cause mortality before and after cardiac resynchronization therapy
Doctor C. Rodriguez-Lopez (Madrid, ES)
Abstract Slides Video
Presentation thumbnail
Mechanical dyssynchrony and response to cardiac resynchronization therapy in heart failure patients with right ventricular pacing: a pre-specified subgroup analysis of the BUDAPEST CRT Upgrade trial
Doctor A. Fabian (Budapest, HU)
Abstract Slides Video
Presentation thumbnail
Beat-to-beat measurement of R-wave peak time for left bundle branch area pacing: man versus machine using a novel automated algorithm
Doctor A. Spadotto (Bologna, IT)
Abstract Slides Video
Presentation thumbnail
Conduction-System pacing Italian Network Group (C-SING): insights from a Nationwide Multicenter Observational Study
Doctor G. Dell'Era (Novara, IT)
Abstract Slides Video

Access the full session

Session thumbnail
Fighting ventricular dyssynchrony: cardiac resynchronisation therapy vs. conduction-system pacing
Video

The Event

Event poster

ESC Congress 2024

2 September 2024 10:55 CET
You may be interested in
thumbnail
Congress Session
Fighting ventricular dyssynchrony: cardiac resynchronisation therapy vs. conduction-system pacing
thumbnail
Congress Session
Late-Breaking Clinical Trials: recent advances in CIED therapies
thumbnail
Congress Presentation
Synchronized left ventricular pacing improves cardiac resynchronization therapy outcomes: insights from AdaptResponse

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources